FDA Webview Site FDA Review Site FDA Updater Site
header.gif
Username:
Password:
 

human drugs
animal drugs
biologics
eirs 483s
medical devices
marketing
email
search our site
  
FDA-RELATED NEWS
 
 
 
TXT Ex-FDA Commissioners Urge Coordinated Covid-19 Plasma Effort
08/04/2020
 
 
TXT Vaccine Decisions ‘Based on Good Science, Data’: Hahn
08/06/2020
 
 
TXT FDA Encouraging ‘Advanced Manufacturing’
08/04/2020
 
 
TXT Experts Weigh-in on Covid Vaccine Deployment
08/06/2020
 
 
TXT Drug Limited Population Pathway Guidance
08/05/2020
 
 
TXT Eight Charged in Clinical Trial Fraud Scheme
08/06/2020
 
 
TXT AbbVie Pays $24 Million Over Calif. Humira Marketing
08/07/2020
 
 
TXT Comments on FDA Data Strategy Modernization
08/05/2020
 
 
TXT End Monopoly Control of Remdesivir: Public Citizen
08/04/2020
 
 
TXT Petition Seeks Ban on Music in DTC Ads
08/03/2020
 
 
TXT Draft Guide on Drug Interaction Assessments
08/07/2020
 
 
TXT Rare Disease Clinical Trial Resource Center Proposed
08/06/2020
 
 
TXT DoJ Seeking $13 Billion for OxyContin Claims: Report
08/05/2020
 
 
TXT Rare Disease Clinical Trial Networks
08/05/2020
 
 
TXT FDA ‘Nimble’ in Pandemic Responses: Azar
08/04/2020
 
 
TXT Product Approval Summaries
08/09/2020
 
 
TXT Since Our Last Issue ...
08/09/2020
 
 
TXT Latest Federal Register Notices
08/09/2020
 
 
TXT FDA Priority Review for Biogen/Eisai BLA for Alzheimer’s
08/07/2020
 
 
TXT Majority of PMRs/PMCs On Schedule: Report
08/06/2020
 
 
TXT CME America Recalls BodyGuard Infusion Pump
08/05/2020
 
 
TXT AbbVie Ends Voyager Therapy Development Pact
08/05/2020
 
 
TXT MasterPharm FDA-483 Released
08/05/2020
 
 
TXT Latest FDA Warning Letters
08/04/2020
 
 
TXT GSK, Sanofi Report Zantac-related Probes
08/04/2020
 
 
TXT MedWatch to Manufacturers Program Discontinued
08/04/2020
 
 
TXT Content/Process Guide for Pediatric Study Plans
08/03/2020
 
 
 
 
The most authoritative FDA news analysis each week is found in the pages of Dickinson's FDA Review. Since 1984, this newsletter has been providing in-depth reports on the most significant FDA developments affecting the pharmaceutical, medical device, biologics and veterinary medicines industries. Unlike other media, FDA Review eliminates time-wasting minutia and presents in clear, concise language the essence of what's really important - and why. It is the publication that FDA officials themselves read. Delivered in the middle of each week, FDA Review presents:
  • The latest agency policy developments, often before they're officially announced;
  • Major news insights, follow-ups and reactions in each product area;
  • Summaries of the latest Warning Letters;
  • The newest product approvals;
  • Summaries of the latest FDA Federal Register notices;
  • Summaries of DDMAC letters;
  • Related industry news capsules;
  • The industry's most concise FDA news index;
  • Inside-FDA news briefs
You can rely on FDA Review to provide only what's important - in the most convenient and time-saving